Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
47results about How to "High-affinity binding" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Polypeptide variants with altered effector function
InactiveUS20060067930A1High affinity bindingWeaker binding affinityCompound screeningNervous disorderEffector functionsMolecular biology
The invention provides polypeptides having IgG Fc regions with amino acid modifications that result in the polypeptides exhibiting altered Fc effector functions.
Owner:GENENTECH INC
Removal of prions from blood, plasma and other liquids
InactiveUS6221614B1High affinityHigh affinity bindingImmobilised enzymesHaemofiltrationBlood plasmaProteinaceous infectious particle
Devices such as flow through columns, substrates such as spherical polymer beads, and methods of using such to remove prions from any liquid sample are disclosed. A surface of a substrate is coated with a prion complexing agent, such as a salt of phosphotungstic acid. Blood or plasma passing through a column containing beads coated with prion complexing agent are rendered prion free.
Owner:RGT UNIV OF CALIFORNIA
Enrichment method for variant proteins with altered binding properties
InactiveUS20060115874A1Valid choiceHigh affinity bindingVirusesPeptide/protein ingredientsEnrichment methodsAntibody fragments
A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.
Owner:GENENTECH INC
Method for identifying modulators of G protein coupled receptor signaling
InactiveUS20070077597A1High affinity bindingAntibacterial agentsAntimycoticsG Protein-Coupled Receptor SignalingPeptide
This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and / or which stabilize a particular conformer of a G protein coupled receptor. Assays, methods of treatment and other methods developed in conjunction with these methods also are disclosed.
Owner:CADEN BIOSCI
Novel dyes for the detection or quantification of desirable target molecules
ActiveUS20060269926A1Fluorescence enhancementHigh affinity bindingMethine/polymethine dyesPeptide/protein ingredientsCombinatorial chemistryOrganic chemistry
The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.
Owner:ENZO LIFE SCI INC
Agents which bind to epitopes of glycoprotein VI
InactiveUS20070071744A1Reduce in quantityRaise the possibilityVirusesPeptide/protein ingredientsEpitopeMedicine
Owner:MUNCH GOTZ +3
Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
Owner:ALBANY MOLECULAR RESEARCH INC
Compositions comprising nucleic acid aptamers
InactiveUS20100254901A1High affinity bindingHigh affinityOrganic active ingredientsPeptide/protein ingredientsDelivery vehicleNucleic acid sequencing
Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.
Owner:SMITH CASSANDRA L
Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
InactiveUS20120157469A1High affinityHigh indexOrganic active ingredientsNervous disorderMelanin-concentrating hormoneCombinatorial chemistry
The present invention relates to piperazinone-substituted tetrahydro-carboline derivatives of formula (I):having the substituents as described herein which are melanin-concentrating hormone (MCH-1) receptor antagonists. The present invention also relates to pharmaceutical compositions including these compounds, and methods of preparation and use thereof.
Owner:ALBANY MOLECULAR RESEARCH INC
Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
InactiveUS8697700B2High affinityHigh indexNervous disorderOrganic chemistryMelanin-concentrating hormoneCombinatorial chemistry
The present invention relates to piperazinone-substituted tetrahydrocarboline derivatives of formula (I):having the substituents as described herein which are melanin-concentrating hormone (MCH-1) receptor antagonists. The present invention also relates to pharmaceutical compositions including these compounds, and methods of preparation and use thereof.
Owner:ALBANY MOLECULAR RESEARCH INC
Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
Owner:ALBANY MOLECULAR RESEARCH INC
Compositions for TRP-M8 binding and radioreceptor methods therewith
InactiveUS6893626B2Easy to detectHigh affinityOrganic chemistry methodsMicrobiological testing/measurementProstate cancer cellBinding study
One embodiment of the invention is a composition that comprises a radioactive 32P or 33P phosphine oxide molecule. The said composition is designed to bind to the transient potential receptor-M8 (TRP-M8) receptor of cells. The radioactive 32P or 33P phosphine oxide ligand may be used for radioreceptor binding studies and for diagnostic studies of cancerous tissues. The TRP-M8 receptor is selectively expressed in malignant tissues such as prostate cancer cells. Affinity of the 32P or 33P phosphine oxide ligand for the TRP-M8 receptor confers selectively and specificity in delivering lethal radiation to the diseased cells.
Owner:WEI EDWARD T
Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
Owner:ALBANY MOLECULAR RESEARCH INC
Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
InactiveUS20120157460A1High affinityHigh indexBiocideNervous disorderMelanin-concentrating hormoneCombinatorial chemistry
The present invention relates to tetrahydro-azacarboline derivatives of formula (I):having the substituents as described herein which are melanin-concentrating hormone (MCH-1) receptor antagonists. The present invention also relates to pharmaceutical compositions including these compounds, and methods of preparation and use thereof.
Owner:ALBANY MOLECULAR RESEARCH INC
Agents which bind to epitopes of glycoprotein vi
ActiveUS20100003244A1Avoid stickingPrevents arterial thrombosisVirusesPeptide/protein ingredientsEpitopeMedicine
Owner:HELMHOLTZ ZENT MUENCHEN DEUT FORSCHUNGSZENTRUM FUER GESUNDHEIT & UMWELT GMBH +1
Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
Owner:ALBANY MOLECULAR RESEARCH INC
Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described in the present invention.
Owner:ALBANY MOLECULAR RESEARCH INC
Follistatin-related fusion proteins and uses thereof
ActiveUS20160311874A1High affinity bindingHigh inhibitionPeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseFollistatin
In certain aspects, the present disclosure provides compositions and methods for inhibiting activity of TGFβ superfamily ligands, particularly ligands such as GDF8, GDF11, activin A, activin B, activin C and activin E, in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent diseases or disorders that are associated with abnormal activity of a follistatin-related polypeptide and / or a follistatin ligand.
Owner:ACCELERON PHARMA INC
Immunoadhesin comprising a glycoprotein VI domain
The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of the immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.
Owner:ADVANCECOR
Immunoadhesin comprising a glycorprotein v1 domain
ActiveUS20050079541A1Avoid stickingPrevents arterial thrombosisOrganic active ingredientsNervous disorderImmunglobulin eFc domain
The present invention provides a fusion protein comprising (a) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of an immunoglobulin or a function-conservative part thereof, characterised by a polypeptide chain having an amino acid sequence as shown in FIG. 7 and whereby the fusion protein is obtainable by a process which provides the fusion protein in the form of a specific dimer.
Owner:ADVANCECOR
Histamine h3 receptor agents, preparation and therapeutic uses
The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
Owner:ELI LILLY & CO
Collagen-binding synthetic peptidoglycans for use in vascular intervention
InactiveUS20150038425A1Low costInhibition of activationOrganic active ingredientsPeptidesCatheterPeptidoglycan
Owner:PURDUE RES FOUND INC
Antibody mediated osseous regeneration
InactiveUS20130122052A1Ability to bindHigh affinityBone implantSkeletal disorderIn vivoDrug biological activity
The invention relates to the field of immunologically reactive molecules used to improve implantable medical devices. Immobilization of selected antibody molecules onto the surface of medical implants enable localization and concentration of in vivo growth factors in a timely manner to enhance the wound healing process following implantation of the device. When in vivo BMP-2 growth factor was captured on an implant device by attached monoclonal antibodies, the biological activity of BMP-2 was enhanced in the vicinity of the implant device. BMP-2 growth factor-specific antibody molecules or their fragments when immobilized on titanium dental or orthopedic implants improve osseo-integration.
Owner:ZADEH HOMAYOUN H
Highly Potent Glucocorticoids
ActiveUS20160251393A1Lowering unwanted side effectImprove effectivenessAntipyreticDigestive systemGlucocorticoidMedicinal chemistry
The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.
Owner:VAN ANDEL RES INST +1
Human-mouse chimeric monoclonal antibody against human platelet membrane glycoprotein Ib alpha and applications of human-mouse chimeric monoclonal antibody
InactiveCN102558354ALess immune responseStrong specificityHybrid immunoglobulinsRadioactive preparation carriersHuman plateletChimeric antibody
The invention belongs to the biotechnology field and particularly relates to a chimeric monoclonal antibody which is capable of being combined with high specificity and high affinity of platelet membrane glycoprotein and has an antithrombotic bioactivity and applications of the chimeric monoclonal antibody. The human-mouse chimeric monoclonal antibody against human platelet membrane glycoprotein Ib alpha is characterized by comprising a mouse heavy chain variable region and a mouse light chain variable region, wherein amino acid sequence of the mouse heavy chain variable region is represented as SEQ ID No.1, and amino acid sequence of the mouse light chain variable region is represented as SEQ ID No.2. Immune reactivity of antibody molecules is mainly produced by a constant region, so that the chimeric antibody containing a human constant region is not easy to generate an anti-mouse immune reaction in human bodies. The monoclonal antibody against platelet glycoprotein (GP) Ib alpha is capable of being combined with high specificity and high affinity of human and rhesus monkey platelet membrane glycoprotein Ib alpha (GP Ib alpha), and the antithrombotic effect is achieved.
Owner:苏州元德维康生物科技有限公司
Anti-her2 antibody and conjugate thereof
ActiveUS20160304621A1Reduce expressionHigh affinityImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAnti her2Small molecule
Owner:REMEGEN CO LTD
Pyrido-/azepino-benzofuran and pyrido-/azepino-benzothiophene mch-1 antagonists, methods of making, and use thereof
Novel MCH-1 receptor antagonists are disclosed. These compounds are used in the treatment of various disorders, including obesity, anxiety, depression, non-alcoholic fatty liver disease, and psychiatric disorders. Methods of making these compounds are also described.
Owner:ALBANY MOLECULAR RESEARCH INC
Transkingdom platform for therapeutic nucleic acid delivery
ActiveUS11312954B2Improve stabilityEnhancing shRNA stability and therapeutic longevitySsRNA viruses negative-senseBacteriaEpitheliumDelivery vehicle
A transkingdom platform for the delivery of therapeutic nucleic acids to epithelial tissues where the nucleic acids are designed to have enhanced stability. The platform offers numerous improvements to prior delivery platforms including expression of the double-stranded RNA binding domain (dsRBD) domains of TAR RNA binding protein (TRBP), knockout of RNase R activity in the bacterial delivery vehicle, and expression of the methyltransferase gene, HEN1, for simultaneous packaging with a therapeutic nucleic acid delivery vehicle.
Owner:SIVEC BIOTECHNOLOGIES LLC
Transgenic mice
ActiveUS20180362666A1High affinity bindingHybrid immunoglobulinsNucleic acid vectorTransgenesisHeavy chain
The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
Owner:CRESCENDO BIOLOGICS
High affinity nucleic acid ligands to lectins
InactiveUS7399752B2High affinity bindingPeptide/protein ingredientsOrganic chemistry methodsE-selectinP-selectin
This invention discloses high-affinity oligonucleotide ligands to lectins, specifically nucleic acid ligands having the ability to bind to the lectins, wheat germ agglutinin, L-selectin, E-selectin and P-selectin. Also disclosed are the methods for obtaining such ligands.
Owner:GILEAD SCI INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com